generic internist

Merck and Schering-Plough Make the Bad News About Vytorin Even Worse

19% of the ENHANCE group who were statin naive showed no benefit either, nor did a subgroup with greater plaque burden, at study entry. This bodes poorly for the Improve -it outcome study and the fate of zetia.